Related references
Note: Only part of the references are listed.Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
R. A. Larson et al.
LEUKEMIA (2012)
Ponatinib in Refractory Philadelphia Chromosome-Positive Leukemias
Jorge E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Amie S. Corbin et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
BCR-ABL kinase is dead; long live the CML stem cell
Alexander Perl et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Inhibitors of the Abl kinase directed at either the ATP- or myristate-binding site
Doriano Fabbro et al.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS (2010)
Beneficial effects of combining a type II ATP competitive inhibitor with an allosteric competitive inhibitor of BCR-ABL for the treatment of imatinib-sensitive and imatinib-resistant CML
E. Weisberg et al.
LEUKEMIA (2010)
HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance
H. Luo et al.
LEUKEMIA (2010)
Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors
Jianming Zhang et al.
NATURE (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
Gianantonio Rosti et al.
BLOOD (2009)
Activity of Bosutinib, Dasatinib, and Nilotinib Against 18 Imatinib-Resistant BCR/ABL Mutants
Sara Redaelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
被撤回的出版物: Disruption of the Bcr-Abl/Hsp90 protein complex: a possible mechanism to inhibit Bcr-Abl-positive human leukemic blasts by novobiocin (Retracted article. See vol. 34, pg. 1722, 2020)
L. X. Wu et al.
LEUKEMIA (2008)
Dulxanthone A induces cell cycle arrest and apoptosis via up-regulation of p53 through mitochondrial pathway in HepG2 cells
Ze Tian et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Myrtucommulone from Myrtus communis induces apoptosis in cancer cells via the mitochondrial pathway involving caspase-9
Irina Tretiakova et al.
APOPTOSIS (2008)
Multiparametric analysis of cells with different mitochondrial membrane potential during apoptosis by polychromatic flow cytometry
Leonarda Troiano et al.
NATURE PROTOCOLS (2007)
Allosteric inhibitors of Bcr-abl-dependent cell proliferation
FJ Adrián et al.
NATURE CHEMICAL BIOLOGY (2006)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Synthesis and biological evaluation of novel curcumin analogs as anti-cancer and anti-angiogenesis agents
BK Adams et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2004)
JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells
E Passegué et al.
CELL (2004)
Normal and leukemic hematopoiesis:: Are leukemias a stem cell disorder or a reacquisition of stem cell characteristics?
E Passegué et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Detection, isolation, and stimulation of quiescent primitive leukemic progenitor cells from patients with acute myeloid leukemia (AML)
YH Guan et al.
BLOOD (2003)
Ionizing radiation and busulfan inhibit murine bone marrow cell hematopoietic function via apoptosis-dependent and -independent mechanisms
A Meng et al.
EXPERIMENTAL HEMATOLOGY (2003)
BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571:: a prospective study
N von Bubnoff et al.
LANCET (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
BJ Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
